SpringWorks Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q4 2017 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
SpringWorks Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q4 2017 to Q4 2024.
  • SpringWorks Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending December 31, 2024 was $5.44M, a 9.05% decline year-over-year.
  • SpringWorks Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $26M, a 13.3% increase year-over-year.
  • SpringWorks Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $26M, a 13.3% increase from 2023.
  • SpringWorks Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $22.9M, a 273% increase from 2022.
  • SpringWorks Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $6.15M, a 1026% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $26M $5.44M -$541K -9.05% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-20
Q3 2024 $26.5M $6.22M +$630K +11.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $25.9M $6.78M +$950K +16.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $25M $7.57M +$2.01M +36.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $22.9M $5.98M +$1.02M +20.6% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-20
Q3 2023 $21.9M $5.59M +$4.75M +567% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $17.2M $5.83M +$5.48M +1575% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $11.7M $5.56M +$5.55M +111040% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $6.15M $4.96M +$4.93M +19724% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-20
Q3 2022 $1.22M $838K +$717K +593% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $499K $348K +$178K +105% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $321K $5K -$225K -97.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $546K $25K -$174K -87.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $720K $121K +$58K +92.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $662K $170K +$13K +8.28% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $649K $230K -$706K -75.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $1.36M $199K -$1.07M -84.3% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $2.42M $63K -$934K -93.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $3.36M $157K -$847K -84.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $4.2M $936K +$657K +235% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $3.55M $1.27M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $997K +$771K +341% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $1M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $279K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q3 2018 $226K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q4 2017 $21K Aug 18, 2017 Dec 31, 2017 10-K 2020-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.